Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat adults with newly diagnosed ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma. Approval based on posit ...